|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 2. Cyclopamine treatment blocks axolotl tail regeneration and a hedgehog
agonist rescues the phenotype. (A-C) Control regenerates 4, 8 and 14 dpa. The
blastema cells are surrounding the ependymal tube at 4 dpa (A). Cartilage has
differentiated 8 dpa (B) and muscle 14 dpa (C). (D-F) Cyclopamine-treated tail
regenerates 4, 8 and 14 dpa. The fin and the ependymal tube have grown, but a
blastema is not visible (compare A and D). No cartilage has differentiated 8
dpa (E) and no muscle has formed 14 dpa (F). (G) Quantification of the lengths
of control and cyclopamine-treated tail regenerates over time. The length of
the regenerating spinal cord is taken as a measurement for overall tail
regeneration. Data points represent the average length of three regenerates;
error bars are standard deviations. (H-J) Cyclopamine-treated regenerate (H),
cyclopamine and agonist-treated regenerate (I), and normal tail regenerate (J)
10 dpa. The tails in I and J are indistinguishable. (K) Quantification of
regenerate lengths (as in G) in indicated conditions shows that 40 nmol/l of
the agonist are sufficient to rescue the cyclopamine effect, whereas 4 nmol/l
are not. The dashed line in A-F and H-J marks the amputation plane. Scale
bars: 0.5 mm.
|
